![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, April 14, 2024 1:50:39 AM
People have dedicated their lives to finding a cure.
Building on expertise to tackle the toughest cancers
Our scientific research has led to critical discoveries in the treatment of blood cancer. Now we’re expanding our knowledge to help treat solid tumors, which represent more than 90% of cancers that affect people.
We leverage our deep understanding of human biology and cutting-edge research technologies to find new ways to improve the lives of people with cancer.
Research interests
We focus on creating targeted medicines that either impede the reproduction of cancer cells or enable their death. We achieve this through immuno-oncology approaches, tumor antigen targeting, and taking advantage of specific tumor dependencies. Our research interests include:
Identifying and targeting mechanisms that allow tumor cells to proliferate and survive, including under-explored forms of regulated cell death, such as necroptosis and ferroptosis
Investigating how to re-energize T cells so that they can retain their fitness and continue to destroy tumor cells
Advancing the use of Antibody Drug Conjugates (ADCs) to target and deliver potent toxins and targeted agents directly to cancer cells
Creating new technologies to improve the efficacy of bispecific biologics in treating both solid tumors and blood cancers, enabling the development of therapies with highly targeted potential
Innovating in the field of targeted protein degradation by designing protein degraders that bind to a protein of interest and trigger its proteasomal degradation
Developing CAR-T cell therapies that attack cancers with healthy donor immune cells engineered to target and kill tumor cells while being resistant to host immune system rejection
https://web.archive.org/web/20231002101632/https://www.abbvie.com/science/areas-of-focus/oncology.html
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM